Research programme: obesity therapy - BEXEL Pharmaceuticals
Alternative Names: BLX-1028; BLX-2002Latest Information Update: 04 Nov 2017
At a glance
- Originator BEXEL Pharmaceuticals
- Class Amino acids; Dipeptides; Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 05 Sep 2007 Preclinical development is ongoing
- 21 Nov 2005 Data presented at the 2005 Annual Meeting of the North American Association for the Study of Obesity (NAASO-2005) have been added to the Obesity pharmacodynamics section